9 Virale hepatitis

1.

Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA 1965;191:541–546.PubMedCrossRef

2.

Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 1973; 182(116):1026–1028.PubMedCrossRef

3.

Eerden LJ Van Der, Bosman A, Duynhoven YT van. [Surveillance of hepatitis A in the Netherlands 1993–2002]. Nederlands Tijdschrift voor Geneeskunde 2004; 148(28):1390–1394.

4.

Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G,et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338(5):286–290.PubMedCrossRef

5.

Fleischer B, Fleischer S, Maier K, Wiedmann KH, Sacher M, Thaler H,et al. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 1990;69(1):14–19.PubMedCentralPubMed

6.

Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. American Journal of Epidemiology 1985;122(2):226–233.PubMed

7.

Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995;171(Suppl 1):S15–S18.PubMedCrossRef

8.

Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992;10(Suppl 1):S18–S20.PubMedCrossRef

9.

Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992;10(Suppl 1): S15–S17.PubMedCrossRef

10.

Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 1994;343(8893): 322–324.PubMedCrossRef

11.

Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K,et al. Hepatitis A booster vaccination: is there a need? Lancet 2003;362(9389):1065–1071.PubMedCrossRef

12.

Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992;14(2):580–586.PubMedCrossRef

13.

Kane MA, Bradley DW, Shrestha SM, Maynard JE, Cook EH, Mishra RP,et al. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984;252(22):3140–3145.PubMedCrossRef

14.

Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc Natl Acad Sci USA 1992;89(17):8259–8263.PubMedCentralPubMedCrossRef

15.

Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Reviews in Medical Virology 2006;16(1):5–36.PubMedCrossRef

16.

Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980;68(6):818–824.PubMedCrossRef

17.

Emerson SU, Purcell RH. Running like water – the omnipresence of hepatitis E. N Engl J Med 2004; 351(23):2367–2368.PubMedCrossRef

18.

Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K,et al. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995;171(2):447–450.PubMedCrossRef

19.

Belabbes EH, Bouguermouh A, Benatallah A, Illoul G. Epidemic non-A, non-B viral hepatitis in Algeria: strong evidence for its spreading by water. Journal of Medical Virology 1985;16(3):257–263.PubMedCrossRef

20.

Tsega E, Krawczynski K, Hansson BG, Nordenfelt E, Negusse Y, Alemu W,et al. Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia. Journal of Medical Virology 1991;34(4): 232–236.PubMedCrossRef

21.

Chau TN, Lai ST, Tse C, Ng TK, Leung VK, Lim W,et al. Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. American Journal of Gastroenterology 2006;101(2):292–296.PubMedCrossRef

22.

Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70(2):252–255.PubMedCrossRef

23.

Khuroo MS, Kamili S, Dar MY, Moecklii R, Jameel S. Hepatitis E and long-term antibody status. Lancet 1993;341(8856):1355.PubMed

24.

Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N,et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356(9):895–903.PubMedCrossRef

25.

Scaglioni PP, Melegari M, Wands JR. Recent advances in themolecular biology of hepatitis B virus. Bailliere’s Clinical Gastroenterology 1996;10(2):207–225.PubMedCrossRef

26.

Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198(2):489–503.PubMedCrossRef

27.

Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus –large-scale analysis using a new genotyping method. J Infect Dis 1997;175(6):1285–1293.PubMedCrossRef

28.

De Franchis RHA, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A,et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39(Suppl 1):S3–S25.

29.

Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13(Suppl 1):S47–S49.PubMedCrossRef

30.

Veldhuijzen I, Conyn-van Spaendonck M, Dorigo- Zetsma J. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking. Infectieziekten Bulletin 1999; 10(9):182–184.

31.

Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292(15):771–774.PubMedCrossRef

32.

Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN,et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263(9):1218–1222.PubMedCrossRef

33.

McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP,et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151(4):599–603.PubMedCrossRef

34.

Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigenpositive hepatitis in Greek adults. Gastroenterology 1987;92(6):1844–1850.PubMed

35.

Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39(Suppl 1):S50–S58.PubMedCrossRef

36.

Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM,et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35(6):1522–1527.PubMedCrossRef

37.

Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM,et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36(2):263–270.PubMedCrossRef

38.

Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A,et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2(8663):588–591.PubMedCrossRef

39.

Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A,et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32(3):294–298.PubMedCentralPubMedCrossRef

40.

Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J,et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994;21(4):656–666.PubMedCrossRef

41.

Jongh FE de, Janssen HL, Man RA de, Hop WC, Schalm SW, Blankenstein M van. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103(5): 1630–1635.PubMed

42.

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–S50.CrossRef

43.

Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507–539.PubMedCrossRef

44.

Janssen HL, Zonneveld M van, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123–129.PubMedCrossRef

45.

Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L,et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32(2):394–399.PubMedCrossRef

46.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206–1217.PubMedCrossRef

47.

Flink HJ, Zonneveld M van, Hansen BE, Man RA de, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. American Journal of Gastroenterology 2006;101(2):297–303.PubMedCrossRef

48.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256–1263.PubMedCrossRef

49.

Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2):61–68.PubMedCrossRef

50.

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357(25):2576–2588.PubMedCrossRef

51.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9):800–807.PubMedCrossRef

52.

Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9):808–816.PubMedCrossRef

53.

Chang TT, Gish RG, Man R de, Gadano A, Sollano J, Chao YC,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001–1010.PubMedCrossRef

54.

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011–1020.PubMedCrossRef

55.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23):2442–2455.PubMedCrossRef

56.

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM,et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46(1):254–265.PubMedCrossRef

57.

Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. American Journal of Preventive Medicine 1998;15(1):73–77.PubMedCrossRef

58.

Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F,et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977;18(12):997–1003.PubMedCentralPubMedCrossRef

59.

Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virusassociated delta antigen to chimpanzees. J Infect Dis 1980;141(5):590–602.PubMedCrossRef

60.

Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM,et al. Structure, sequence and expression of the hepatitis delta viral genome. Nature 1986; 323(6088):508–514.PubMedCrossRef

61.

Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997;25(3):728–734.PubMedCrossRef

62.

Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S,et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000;32(4 Pt 1):824–827.PubMedCrossRef

63.

Rizzetto M, Ponzetto A, Forzani I. Epidemiology of hepatitis delta virus: overview. Progress in Clinical and Biological Research 1991;364:1–20.PubMed

64.

Farci P. Delta hepatitis: an update. J Hepatol 2003; 39(Suppl 1):S212–S219.PubMedCrossRef

65.

Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P,et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987;5(3):274–281.PubMedCrossRef

66.

Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G,et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000;46(3): 420–426.PubMedCentralPubMedCrossRef

67.

Aragona M, Macagno S, Caredda F, Crivelli O, Lavarini C, Maran E,et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987;1(8531):478–480.PubMedCrossRef

68.

Buti M, Esteban R, Jardi R, Esteban JI, Guardia J. Serological diagnosis of acute delta hepatitis. Journal of Medical Virology 1986;18(1):81–85.PubMedCrossRef

69.

Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY,et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995;108(3):796–802.PubMedCrossRef

70.

Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P,et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330(2):88–94.PubMedCrossRef

71.

Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359–362.PubMedCrossRef

72.

Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25(6):1527–1538.PubMedCrossRef

73.

Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21(2):570–583.PubMedCrossRef

74.

Hepatitis C – global prevalence (update). Rélève Épidemiologique Hebdomadaire/Section d’Hygiene du Secretariat de la Societé des Nations = Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations 1999;74(49):425–427.

75.

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41–52.PubMedCrossRef

76.

Hattum J van. Health strategy on HCV in The Netherlands. Acta Gastro-enterologica Belgica 2002;65(2):115–117.PubMed

77.

Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F,et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145(6):886–893.PubMedCrossRef

78.

Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C,et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330(11):744–750.PubMedCrossRef

79.

Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35–S46.CrossRef

80.

Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology 1997;112(2): 463–472.PubMedCrossRef

81.

Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D,et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28(6):1687–1695.PubMedCrossRef

82.

Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA,et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40(5):823–830.PubMedCrossRef

83.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529–538.PubMedCrossRef

84.

Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B,et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325(2): 98–104.PubMedCrossRef

85.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975–982.PubMedCrossRef

86.

Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine 2004;140(5):346–355.PubMedCrossRef

87.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958–965.PubMedCrossRef

88.

Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J,et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40(6):993–999.PubMedCrossRef

89.

Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M,et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352(25):2609–2617.PubMedCrossRef

90.

Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J,et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44(1):97–103.PubMedCrossRef

91.

McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44(2):411–421.PubMedCrossRef

92.

Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H,et al. Molecular cloning and disease association of hepatitis G virus: a transfusiontransmissible agent. Science 1996;271(5248):505–508.PubMedCrossRef

93.

Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochemical and Biophysical Research Communications 1997; 241(1):92–97.PubMedCrossRef

Bohn Stafleu van Loghum

9 Virale hepatitis

Samenvatting

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen